Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138925 | 1.00 | LMNA (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL11291906 | 1.00 | LMNA (0.50) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL11294170 | 0.93 | HTT (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL11310616 | 0.93 | HTT (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL11048769 | 0.93 | HTT (0.52) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL8897257 | 0.88 | LMNA (0.46) | LMNASMN1; SMN2HTTFOLH1GAA | |
| SCHEMBL11294755 | 0.88 | LMNA (0.46) | LMNASMN1; SMN2HTTFOLH1GAA | |
| SCHEMBL8897264 | 0.88 | LMNA (0.46) | LMNASMN1; SMN2HTTFOLH1GAA | |
| SCHEMBL8209334 | 0.85 | HTT (0.53) | LMNASMN1; SMN2SLC1A3SLC1A1HTT | |
| SCHEMBL794883 | 0.85 | LMNA (0.51) | LMNASMN1; SMN2SLC1A3SLC1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0048613-B1 | 4-0-SUBSTITUTED -2-DEOXYSTREPTAMINE AMINOGLYCOSIDE DERIVATIVES, THEIR PREPARATION AND FORMULATIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1985-01-23 | — | — | EP | claimed |
| US-4424345-A | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | claimed |
| US-4424344-A | 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | claimed |
| EP-0048614-A1 | 1-N-acylated and 1-N-alkylated derivatives of 4-0-substituted -2-deoxystreptamine aminoglycosides | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | claimed |
| US-4136254-A | PROCESS OF SELECTIVELY BLOCKING AMINO FUNCTIONS IN AMINOGLYCOSIDES USING TRANSITION METAL SALTS AND INTERMEDIATES USED THEREBY | SCHERING CORPORATION (US) | 1979-01-23 | — | — | US | claimed |
| US-7759482-B2 | Aminoglycosides as antibiotics | WAYNE STATE UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070203081-A1 | AMINOGLYCOSIDES AS ANTIBIOTICS | WAYNE STATE UNIVERSITY | 2007-08-30 | — | — | US | disclosed |
| US-7220727-B2 | For therapy of bacterial infection in a mammal | WAYNE STATE UNIVERSITY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050171035-A1 | For therapy of bacterial infection in a mammal | WAYNE STATE UNIVERSITY | 2005-08-04 | — | — | US | disclosed |
| WO-2002057281-A2 | AMINOGLYCOSIDES AS ANTIBIOTICS | WAYNE STATE UNIVERSITY (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-0185323-B1 | 2',3'-DIDEOXY-2'-FLUOROKANAMYCIN A AND 1-N-(ALPHA-HYDROXY-OMEGA-AMINOALKANOYL) DERIVATIVES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4661474-A | ANTIBIOTICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1987-04-28 | — | — | US | disclosed |
| EP-0000473-A1 | Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives | Technobiotic Ltd. (CH) | 1979-02-07 | — | — | EP | disclosed |
| US-4136254-A | PROCESS OF SELECTIVELY BLOCKING AMINO FUNCTIONS IN AMINOGLYCOSIDES USING TRANSITION METAL SALTS AND INTERMEDIATES USED THEREBY | SCHERING CORPORATION (US) | 1979-01-23 | — | — | US | disclosed |
| US-4053591-A | 5-DEOXY-4,6-DI-O-(AMINOGLYCOSYL)-1,3-DIAMINOCYCLITOLS, METHODS FOR THEIR MANUFACTURE, METHOD FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR | SCHERING CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-4029882-A | BACTERICIDES | SCHERING CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-4002742-A | 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor | SCHERING CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
| US-4000261-A | 5-EPI-4,6-DI-O-(AMINOGLYCOSYL)-2-DEOXYSTREPTAMINES, METHODS FOR THEIR MANUFACTURE AND INTERMEDIATES USEFUL THEREIN, METHODS FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-4000262-A | 5-EPI-AMINO AND 5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES 1-N-ALKYL-5-EPI-AMINO AND 1-N-ALKYL-5-EPI-AZIDO-4,6-DI-O-(AMINOGLYCOSYL)-2,5-DIDEOXYSTREPTAMINES | SCHERING CORPORATION (US) | 1976-12-28 | — | — | US | disclosed |
| US-3974137-A | ANTIBACTERIAL, ALDEHYDE BLOCKING AGENT | BRISTOL-MYERS COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171035-A1 | For therapy of bacterial infection in a mammal | PIGS, BPGM, NPEPPS | LMNA 1655/4885SMN1; SMN2 4637/4885SLC1A3 1166/4885 |
| US-20070203081-A1 | AMINOGLYCOSIDES AS ANTIBIOTICS | PIGS, ALG8, NPEPPS | LMNA 801/4885SMN1; SMN2 3844/4885SLC1A3 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.